Indegene Ltd., a leading technology-led healthcare solutions provider, reported strong financial performance for the fiscal year 2024 (FY24).
Key Highlights:
Revenue: Surpassed ₹2,500 crore, marking a 12.3% YoY increase.
EBITDA: Increased by 28.6% YoY.
PAT (Profit After Tax): Grew by 26.5% YoY.
EBITDA Margin: Expanded by 286 bps YoY.
PAT Margin: Improved by 146 bps YoY.
Additional Insights:
The company's strong performance in FY24 can be attributed to its focus on digital transformation and expanding its customer base in the global life sciences industry. Indegene's comprehensive portfolio of solutions, ranging from clinical development to commercialization, has been instrumental in driving its growth.
For further analysis and information:
ICICI Direct Analysis: https://www.icicidirect.com/research/equity/rapid-results/indegene-ltd
5paisa Share Price: https://www.5paisa.com/stocks/indgn-share-price
Comments